{"id":"NCT02121262","sponsor":"Allergan","briefTitle":"A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema","officialTitle":"Dexamethasone Posterior Segment Drug Delivery System Versus Laser Photocoagulation in Patients With Diabetic Macular Edema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-08","primaryCompletion":"2019-11-01","completion":"2019-11-01","firstPosted":"2014-04-23","resultsPosted":"2020-11-17","lastUpdate":"2020-11-17"},"enrollment":284,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Edema"],"interventions":[{"type":"DRUG","name":"Dexamethasone","otherNames":["OZURDEX®"]},{"type":"PROCEDURE","name":"Laser Photocoagulation","otherNames":[]}],"arms":[{"label":"Laser Photocoagulation","type":"OTHER"},{"label":"Dexamethasone","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and efficacy of 700 μg dexamethasone versus laser photocoagulation in participants with diabetic macular edema (DME).","primaryOutcome":{"measure":"Average Change From Baseline (CFB) in Best Corrected Visual Acuity (BCVA) in the Study Eye","timeFrame":"Baseline to Month 12","effectByArm":[{"arm":"Laser Photocoagulation","deltaMin":1.4,"sd":0.65},{"arm":"Dexamethasone","deltaMin":4.3,"sd":0.61}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0011"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":18,"countries":["China","Philippines"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":129},"commonTop":["Intraocular pressure increased","Visual impairment","Cataract","Upper respiratory tract infection","Dry eye"]}}